Evidence map›Paper›PMID 39576455›Full record

ArticleAnnals of surgical oncology2025

Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma.

Alex B Blair, Shannon N Radomski, Joanne Chou, Mengyuan Liu, Thomas Clark Howell, Wungki Park, Eileen M O'Reilly, Lei Zheng, Vinod P Balachandran, Alice C Wei and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Alex B BlairDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Shannon N RadomskiDepartment of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Joanne ChouDepartment of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mengyuan LiuDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Thomas Clark HowellDepartment of Surgery, Duke University Hospital, Durham, NC, USA.
Wungki ParkDepartment of Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eileen M O'ReillyDepartment of Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lei ZhengDepartment of Oncology, Johns Hopkins Hospital, Baltimore, MD, USA.
Vinod P BalachandranDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alice C WeiDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
T Peter KinghamDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael I D'AngelicaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jeffrey DrebinDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sabino ZaniDepartment of Surgery, Duke University Hospital, Durham, NC, USA.
Dan G BlazerDepartment of Surgery, Duke University Hospital, Durham, NC, USA.
Richard A BurkhartDepartment of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
William R BurnsDepartment of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kelly J LafaroDepartment of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Peter J AllenDepartment of Surgery, Duke University Hospital, Durham, NC, USA.
William R JarnaginDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael E LidskyDepartment of Surgery, Duke University Hospital, Durham, NC, USA.
Jin He *Department of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jhe11@jhmi.edu.
Kevin C Soares *Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. soaresk@mskcc.org.ORCID http://orcid.org/0000-0002-0406-017X

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundPancreatic acinar cell carcinoma (pACC) is a rare neoplasm of the exocrine pancreas. There is a dearth of information about tumor characteristics and patient outcomes. This study describes the clinical characteristics, genetic alterations, and survival outcomes of resected pACC. PATIENTS AND

methodsConsecutive patients undergoing pancreatectomy for pathologically confirmed pACC from 1999 to 2022 across three high-volume pancreas surgery centers were analyzed. Patient demographics, tumor characteristics, treatment data, and genetic sequencing were obtained through retrospective abstraction.

resultsA total of 61 patients with resected pACC were identified. Median overall survival (OS) was 73 months and median recurrence free survival was 22 months. Nine patients underwent resection for oligometastatic disease; median OS was not reached after a median follow-up of 31 months from date of metastasectomy. Adjuvant chemotherapy was administered in 67% of patients with FOLFOX/FOLFIRINOX (5-fluorouracil, leucovorin, oxaliplatin, ± irinotecan) the most common regimen (58%). Sequencing data were obtained in 47 (77%) patients. A mutation in at least one of three core genes associated with the homologous recombination repair (HRR) pathway (BRCA1, BRCA2, or PALB2) occurred in 26% (n = 12) with BRCA2 the most frequently identified. A mutation in any other "non-core" gene associated with DNA damage repair or the HRR pathway was identified in 45% (n = 21) with a high tumor mutational burden of > 10 mutations per megabase in 13%.

conclusionsResection of pACC is associated with favorable survival outcomes, even in the setting of oligometastatic disease. Mutations in the HRR pathway are common, providing opportunities for potential targeted therapeutic options.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Acinar CellMutationPancreatectomyPancreatic NeoplasmsAdultAgedBRCA1 ProteinBRCA2 ProteinChemotherapy, AdjuvantFanconi Anemia Complementation Group N ProteinFemaleFluorouracilFollow-Up StudiesHumansBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanFanconi Anemia Complementation Group N ProteinFluorouracilIrinotecanLeucovorinPALB2 protein, humanAcinar cell carcinomaHomologous repair deficiencyPancreatic exocrine cancerSurvivalWhole exome sequencing

Identifiers

PMID39576455
PMCPMC11811437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.